Stockscreener 앱 받기
106.68
4.82%
-5.40
시간 외 거래:
106.68
전일 마감가:
$112.08
열려 있는:
$110.83
하루 거래량:
765.70K
Relative Volume:
0.81
시가총액:
$8.87B
수익:
$51.48M
순이익/손실:
$-315.00M
주가수익비율:
-29.88
EPS:
-3.5708
순현금흐름:
$-244.00M
1주 성능:
+0.66%
1개월 성능:
-7.20%
6개월 성능:
+20.50%
1년 성능:
+78.13%
1일 변동 폭
$106.52
$112.06
1주일 범위
$103.45
$115.81
52주 변동 폭
$55.26
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
106.68 | 8.87B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-09 | 개시 | Raymond James | Outperform |
| 2026-09-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-07-30 | 개시 | Deutsche Bank | Hold |
| 2026-05-06 | 개시 | Canaccord Genuity | Buy |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68 - MarketBeat
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock - Investing.com
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock By Investing.com - Investing.com UK
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - Stock Titan
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - Stock Titan
Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions - Simply Wall Street
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc.Common Stock (Nasdaq:KYMR) Price Chart - The Chronicle-Journal
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Australia
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com Canada
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Australia
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Canada
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - marketscreener.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kymera Therapeutics Inc 주식 (KYMR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mainolfi Nello | Officer |
Oct 01 '26 |
Proposed Sale |
111.79 |
30,000 |
3,353,700 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Oct 01 '26 |
Sale |
113.80 |
30,000 |
3,413,917 |
666,568 |
| Brian Adams | Officer |
Sep 04 '26 |
Proposed Sale |
117.28 |
6,371 |
747,191 |
0 |
| Adams Brian | Chief Legal Officer |
Sep 04 '26 |
Sale |
116.83 |
6,371 |
744,297 |
50,254 |
| JEREMY CHADWICK | Officer |
Sep 02 '26 |
Proposed Sale |
119.05 |
10,879 |
1,295,145 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Jul 07 '26 |
Option Exercise |
2.08 |
50,000 |
104,000 |
716,568 |
| Mainolfi Nello | Officer |
Jul 07 '26 |
Proposed Sale |
119.00 |
50,000 |
5,950,000 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Jul 07 '26 |
Sale |
119.00 |
50,000 |
5,950,000 |
666,568 |
| Mainolfi Nello | Chief Executive Officer |
Jul 01 '26 |
Sale |
115.29 |
80,000 |
9,223,527 |
666,568 |
| Mainolfi Nello | Officer |
Jul 01 '26 |
Proposed Sale |
114.29 |
80,000 |
9,143,200 |
0 |
4.41%
자본화:
|
볼륨(24시간):